PT Prodia Widyahusada Tbk
IIDX:PRDA3,590.00
IDR
+90.00
(+2.57%)
ISIN
ID1000138001
Return %
Stock
S&P 500
1Y
39.15
14.20
3Y
-44.56
81.12
5Y
-43.02
68.34
Capital Structure
IDR
•
in mil. unless spec.Working Capital
IDR
•
in mil. unless spec.Growth Rates
IDR
•
in mil. unless spec.Quarterly Revenue
IDR
•
in mil. unless spec.Quarterly Earnings Per Share
IDR
•
in mil. unless spec.Quarterly Dividends Per Share
IDR
•
in mil. unless spec.Company Description
- CEO
- Liana Kuswandi
- Full Time Employees
- 2,908
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Prodia Tower Jakarta JK Indonesia 10430
- IPO Date
- Dec 7, 2016
- Website
- prodia.co.id
- Similar Companies
- Business
- PT Prodia Widyahusada Tbk is an Indonesian clinical laboratory services company founded in 1973 and headquartered in Jakarta Pusat. The company offers a comprehensive range of diagnostic and health services including laboratory tests, genomic testing, non-laboratory diagnostics, panel testing, vaccination services, and doctor consultations both in-person and via teleconsultation. It operates Prodia specialty clinics serving various patient segments such as women's health, children's health, and senior health, as well as home service options and research support. The business also manages a nationwide network of over 300 outlets and has strong presence in major regions including Jakarta, Greater Jakarta, Sumatera, Java, Bali, Kalimantan, Sulawesi, and Papua. PT Prodia Widyahusada Tbk functions as a subsidiary of PT Prodia Utama. In the past 1-2 years, Prodia has significantly expanded its product offerings especially in genomic testing, launching around 10 new test types to align with its commitment to innovation. The company has undergone a digital transformation that boosted customer acquisition by over 20%, enhanced its market share to approximately 40.5%, and improved operational economies of scale through a scalable hub and spoke business model centered on core referral labs in Jakarta, Surabaya, Medan, and Makassar. Despite some recent profit pressure due to rising digital and IT costs, Prodia continues to invest in expanding its clinical and specialty clinic services, including standalone and branch-based clinics, while supporting health programs such as the BPJS Prolanis. Prodia maintains accreditation from the College of American Pathologists (CAP) and offers more than 3,000 tests, catering primarily to the Indonesian healthcare diagnostics market. The company targets health supporting services and paramedical activities, focusing on private healthcare consumers and institutional clients including hospitals and biotech sectors through contract research organization (CRO) laboratory services. Prodia emphasizes personalized and precision medicine approaches across multiple customer segments, reinforcing its leadership position as the largest private independent clinical laboratory chain in Indonesia with a market share of about 35% by revenue. Recent strategic moves include strengthening its digital capabilities and omnichannel marketing efforts, expanding specialty clinic footprints, and enhancing referral lab operations to sustain growth and market leadership.